Trials / Completed
CompletedNCT02848170
Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension
An Exploratory Study of CS-3150 to Evaluate the Relation Between Antihypertensive Effect and Baseline Factors Compared to Olmesartan Medoxomil in Patients With Essential Hypertension
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Daiichi Sankyo Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
Phase 3 study to examine the relation between antihypertensive effect and baseline factors exploratively, compared to olmesartan medoxomil in patients with essential hypertension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CS-3150 | CS-3150 2.5mg, oral |
| DRUG | olmesartan medoxomil | olmesartan medoxomil 10 mg, oral |
Timeline
- Start date
- 2016-08-01
- Primary completion
- 2017-04-01
- Completion
- 2017-04-01
- First posted
- 2016-07-28
- Last updated
- 2018-12-21
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02848170. Inclusion in this directory is not an endorsement.